BIO maps incentives for neglected diseases
Executive Summary
The Biotechnology Industry Organization highlights incentives for innovation for diseases in developing countries, including Advanced Market Commitments, R&D tax incentives, priority review vouchers, transferable exclusivity, Track II patents and even prizes in the paper released June 18 at the BIO International Convention in San Diego, Calif. Some of the incentives are already being adopted. For example, the FDA Amendments Act includes a mechanism to encourage development of tropical diseases - including AIDS - by offering sponsors a transferable priority review voucher. Additionally, an investigational version of Wyeth's currently marketed Prevnar is an anticipated candidate for a pediatric pneumococcal AMC, as is an investigational vaccine, Streptorix, being developed by GlaxoSmithKline (1"The Pink Sheet," Nov. 26, 2007, p. 24)
You may also be interested in...
Wyeth, GSK Vaccines May Get Sales Boost Under Pilot For Developing Countries
Pediatric pneumococcal vaccines in development by Wyeth and GlaxoSmithKline could be the first products to benefit from a pilot program designed to create an incentive to develop vaccines that treat the diseases of the developing world
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.